Detail akcie Fluidigm online

Business Summary: Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Standard Biotools Inc revenues increased 57% to $82.7M. Net loss applicable to common stockholders increased from $33.9M to $123.9M. Revenues reflect Proteomics segment increase of 93% to $64.4M, Americas segment increase from $22.1M to $44.5M, Asia-Pacific segment increase of 33% to $15.2M, Europe & Middle East & Africa (EMEA) segment increase of 20% to $23.1M.